Novo Nordisk said Thursday it would take legal action against a US chain offering a copycat of the new pill version of its Wegovy weight-loss drug.<\/p>\n
The Danish company only began selling Wegovy in pill form last month after having received approval from the US Food and Drug Administration, but the telehealth company Hims & Hers has begun advertising cheaper versions.<\/p>\n
“This is another example of Hims & Hers’ historic behaviour of duping the American public with knock-off GLP-1 products,” said Novo Nordisk in a statement, referring to the hormone in Wegovy that regulates blood glucose levels and appetite.<\/p>\n
“Novo Nordisk will take legal and regulatory action to protect patients, our intellectual property and the integrity of the US gold-standard drug approval framework,” it added.<\/p>\n
Limited production capacity for the blockbuster drug led the FDA to temporarily allow pharmacies to create so-called “compound” or copycat versions of Wegovy and Ozempic, an analogue used to treat diabetes.<\/p>\n
That authorisation expired last May 22 but Novo Nordisk has complained of copycat versions of its drugs still being available.<\/p>\n
Shares in Novo Nordisk have taken a beating this week after it warned of lower sales revenue in the United States as intensified competition pushes down prices.<\/p>\n
ef\/rl\/jj<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk said Thursday it would take legal action against a US chain offering a copycat of the…\n","protected":false},"author":2,"featured_media":617,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[688,699,698,691,393,692,700,701,703,702,690,696,694,272,695,693,697,689],"class_list":{"0":"post-616","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-afp","9":"tag-chemicals-in-medicine","10":"tag-clinical-medicine","11":"tag-drugs","12":"tag-health","13":"tag-health-care","14":"tag-health-care-industry","15":"tag-health-sciences","16":"tag-industries-economics","17":"tag-medical-specialties","18":"tag-medical-treatments","19":"tag-medicinal-chemistry","20":"tag-medicine","21":"tag-novo-nordisk","22":"tag-pharmaceutical-sciences","23":"tag-pharmacology","24":"tag-pharmacy","25":"tag-semaglutide"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=616"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/616\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/617"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=616"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}